Orchid BioSciences Reports 29-Percent Jump in Q4 Revenue; R&D, Profit Increase | GenomeWeb

This update serves to correct three errors: Orchid generated $13.7 million in total revenue during the fourth quarter of 2003, not $12.6 million, as was reported. Additionally, Orchid's net earnings per share during the fourth quarter 2004 was $.03, not $.04, as was reported; and the company posted a net loss of $7.3 million during the fourth quarter of 2003, as opposed to $7.2 million, as was reported.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.